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Development of innovative high throughput technologies 
has enabled a variety of molecular landscapes to be inter-
rogated with an unprecedented degree of detail. Emer-
gence of next generation nucleotide sequencing methods, 
advanced proteomic techniques, and metabolic profiling 
approaches continue to produce a wealth of biological 
data that captures molecular frameworks underlying phe-
notype. The advent of these novel technologies has sig-
nificant translational applications, as investigators can now 
explore molecular underpinnings of developmental states 
with a high degree of resolution. Application of these lead-
ing-edge techniques to patient samples has been success-
fully used to unmask nuanced molecular details of disease 
vs healthy tissue, which may provide novel targets for palli-
ative intervention. To enhance such approaches, concomi-
tant development of algorithms to reprogram differentiat-
ed cells in order to recapitulate pluripotent capacity offers 
a distinct advantage to advancing diagnostic methodol-
ogy. Bioinformatic deconvolution of several “-omic” lay-
ers extracted from reprogrammed patient cells, could, in 
principle, provide a means by which the evolution of indi-
vidual pathology can be developmentally monitored. Sig-
nificant logistic challenges face current implementation of 
this novel paradigm of patient treatment and care, how-
ever, several of these limitations have been successfully ad-
dressed through continuous development of cutting edge 
in silico archiving and processing methods. Comprehen-
sive elucidation of genomic, transcriptomic, proteomic, 
and metabolomic networks that define normal and patho-
logical states, in combination with reprogrammed patient 
cells are thus poised to become high value resources in 
modern diagnosis and prognosis of patient disease.
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Disease anticipation prior to symptomatic presentation 
provides multiple pre-emptive opportunities for clinical 
management. Palliative or curative effectiveness is en-
hanced by early detection of disease-promoting factors, as 
early stage treatment can preclude catastrophic pathologi-
cal progression. Translationally relevant risk factors can be 
identified through techniques that interrogate and assess 
biological marker status (1), where methods such as gene 
overexpression, peptide fragment enrichment, and me-
tabolite concentration can be respectively used to diag-
nose diseases such as clinical carcinoma (2), cardiovascular 
pathologies (3), and diabetes (4).
Distinctions among high throughput methodologies con-
fer specific advantages and disadvantages that determine 
efficiency and application of genomic, proteomic, or me-
tabolomic approaches. For example, genes validated from 
tissue biopsies and measurement of glucose uptake with 
the glucose analogue tracer 18F-fluoro-2-deoxyglucose 
are among the tools that oncologists rely upon to diag-
nose and manage tumors (5). Experimental confirmation 
of gene expression differences in normal vs tumor samples 
can then be used to determine tumor aggressiveness and 
provide prognosis and susceptibility profiles (6).
Differential gene expression provides direct indicators of 
genetic background and transcriptome reprogramming as 
a consequence of evolving disease, but cannot provide in-
formation regarding dynamic functional changes. Peptide 
screening, a hallmark of proteomic analyses, can be em-
ployed to obtain this type of information (7,8). For exam-
ple, palliation of cardiopathology is more effective when 
combined with a proteomic strategy to identify peptide 
fragments released into patient serum as a result of cardiac 
dysfunction (9,10).
Advantages of genomic/transcriptomic and proteomic 
screens provide relevant data for clinical management of 
disease, though the techniques themselves require several 
days to weeks for quality-controlled processing and data 
analyses. Metabolic screening offers a distinct advantage 
in that samples can be assayed to provide feedback on dis-
ease states with greater celerity than the “-omic” approaches 
described previously. Though the prototype for metabolite 
analysis is glucose monitoring used in diabetes manage-
ment (11), other examples of clinical metabolomics exist 
(12,13). Significantly, stabilization and processing of evanes-
cent metabolites for precise and accurate measurements 
of metabolic states in diseased vs non-diseased patients 
is critical to all metabolomic profiling approaches.
These techniques allow deep interrogation of the molecu-
lar complement that comprises the functional background 
of a cell or tissue sample. Clinical application of these ap-
proaches gains significant leverage when combined with 
a pluripotent cell platform that can provide readouts of the 
molecular origin of disease phenotype.
The PoST-genomiC eRA AnD STem CeLLS
Current generation high throughput technology, origi-
nally developed to address rapid high volume sequencing 
needs (14), has galvanized genomic, transcriptomic, pro-
teomic, and metabolomic platform development. Depth 
and resolution of biomarker composition analysis has in-
creased significantly, which has necessitated development 
of commensurate in silico methods. Indeed, bioinformat-
ic approaches that employ systems biology principles to 
parse multidimensional biodata extracts multiple levels 
of integrated information, and application of such tech-
niques to targeted stem cell populations may offer novel 
modalities of advanced pathology diagnosis.
Stem cells possess a unique potential to anticipate disease 
phenotypes as they harbor the fundamental molecular 
baseline that gives rise to genomic content and its derived 
transcriptomic, proteomic, and metabolomic strata. Inter-
rogation of these “-omic” layers provides rich data to de-
convolute systems biology of developmental programs, 
elucidation of which is critical to understanding clinical 
pathology etiology. Molecular cartography of pluripotent 
disease-prone backgrounds would facilitate pre-emptive 
diagnosis through comparison of healthy wild type tem-
plates with diseased states (3,15,16), as well as offer a tool 
for dynamic prognosis to track changes concomitant with 
pathological progression or assessment of response to 
therapeutic intervention (3). While a variety of stem cells 
offer specific clinical advantages, pluripotent stem cells 
may be ideal candidates for patient applications (17,18).
Embryonic stem (ES) cells can be harvested and profiled to 
establish a molecular baseline for comparison to diseased 
genomes. Recent data indicate that in addition to patient-
donated material, patient-specific ES cells can be success-
fully cloned for potential therapeutic applications (19). 
Partly in an attempt to circumvent moral, legal, and ethi-
cal disputes associated with human ES studies, discovery 
and development of a molecular algorithm to reprogram 
cells from a committed fate to a pluripotent state (20) may 
provide a viable alternative to, and significant advantages 
over, ES cells in development of systems biology strategies 
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for comprehensive disease resolution spanning embryonic 
to differentiated phenotypes (21). Generation and estab-
lishment of disease- and patient- specific embryonic stem 
cell lines is valuable for its potential to provide individual-
ized experimental cell models, where tailored experimen-
tal design, with a focus on personalized therapeutic strate-
gies, can be performed (22). Induced pluripotent stem (iPS) 
cells, as part of an advanced disease management strategy, 
have the potential to advance clinical diagnostics, though 
several obstacles face implementation of this strategy.
Full equivalency of induced compared to developmentally 
derived stem cells must be demonstrated to employ repro-
grammed cells as proxies for a naturally occurring primordial 
baseline (23). Indeed, though genetic and epigenetic varia-
tion between ES and iPS cells confers a difference in tum-
origenic potential (24), extraction of a conserved molecular 
signature may circumvent limitations associated with ge-
netic and epigenetic heterogeneity (17,25). Furthermore, 
restriction of bioinformatic interrogation to iPS cell lines de-
rived from the same patient can be used to limit influence of 
epigenetic variation among samples. In combination with 
quality control measures to ensure consistent cell culture 
technique and microenvironment exposure that may other-
wise lead to respective chromosomal segregation and epi-
genetic changes (26,27), preparation of human iPS cell lines 
for clinical diagnostic applications may be feasible.
Systems-wide biodiagnostics, in which entire molecular 
complements can be assayed, provides an opportunity to 
comprehensively quantify molecular elements that under-
lie normal as well as clinically dysfunctional development. 
Current advances in cellular reprogramming methodolo-
gy, along with the advent of high throughput technology 
and advanced bioinformatic computational approaches, 
presents a unique confluence of molecular tools and tech-
niques by which diseased cells can be reprogrammed to 
a primordial state (28), then scrutinized for signature el-
ements that segregate them from normal phenotypes. 
Thus, comprehensive bioinformatic dissection of pheno-
typic regressed ES cells offers opportunities to discover 
novel molecular targets for early intervention or palliation 
in advance of clinical manifestation, that may be found at 
genomic, transcriptomic, proteomic, and metabolomic 
levels, or any combination thereof.
genomiCS
The genomic, transcriptomic, proteomic, and metabolo-
mic elements of systems biology approaches provide bi-
ological information unique to each layer of the molecu-
lar network, and a variety of specialized techniques exist 
to interrogate each. From a molecular network ontogeny 
perspective, the genome is the origin of subsequent tran-
scriptomes, proteomes, and metabolomes, and is a useful 
starting point for a discussion regarding roles the genome 
has played in translational diagnosis.
The genome is the molecular blueprint composed of gen-
ic and non-genic sequences that ultimately determine 
organismal phenotype (29), and the advent of whole ge-
nome sequencing has catapulted the field forward (30), 
as well as given rise to new specialties (31). This advance 
has spurred a renaissance of clinical genetics, as present 
genetic counseling techniques are based on reductionist 
“one gene, one disease” strategies, a paradigm which has 
successfully guided identification of the genetic basis for 
many clinically relevant diseases. Resolution of polygenic 
pathologies, as well as disease progression impacted by 
heritable epigenetic modifications, however, cannot be ef-
fectively addressed by this diagnostic modality. To resolve 
the problem of multigene and/or epigenetically triggered 
pathology, genome-wide association studies (GWAS) have 
been used to identify and define multiple susceptibil-
ity loci correlated with disease presentation (32). This ap-
proach is used to bioinformatically mine complex genomic 
data sampled from large populations to identify key genes 
that associate with disease. Paradoxically, the large sample 
sizes that provide robustness to a GWAS approach pre-
vents direct application toward personalized therapeutic 
approaches, a limitation that must be considered when 
evaluating genomic diagnostic technologies for individu-
alized patient application.
Implementation of genome-wide analyses to stem cell 
(re)programming in the context of therapeutic applica-
tion has yielded a rich body of novel data that provides 
details on changes in genomic regulatory elements, epige-
nomic landscape transitions, and three-dimensional chro-
matin shifts critical to the process of phenotype (re)acqui-
sition (28,33). These levels of genomic complexity imposed 
can now be resolved with high precision using modern 
methodology (34) to facilitate fine resolution of the full ge-
nomic blueprint, critical for translational application.
TRAnSCRiPTomiCS
The transcriptome is the full complement of RNA pro-
duced in response to signaling cues processed by, and 
transcribed from, the underlying genome, and tech-
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nology and methods employed for genomic deconstruction 
are applicable to transcriptome resolution. Comprehensive 
transcript analysis is an attractive option for biomarker iden-
tification, as panels of differentially expressed genes (DEGs) 
are used to establish indices of disease progression (35). Pri-
oritized gene lists can be further analyzed for gene ontology 
enrichment and bionetwork analyses to respectively iden-
tify and quantitate the molecular gestalt underlying normal 
or diseased phenotype progression (36).
Transcriptome deconvolution has been used to identify 
contributions of specific genes during the process of so-
matic cell reprogramming (37), and a variety of criteria 
unique to high throughput RNA analysis that derive from 
diverse RNA heterogeneity (38) play critical roles in eluci-
dating transcriptome dynamics of differentiation. An es-
sential characteristic of the transcriptome is (auto)regu-
lation facilitated by subtle intra-RNA dynamics (39,40), 
however interactions of regulatory non-coding RNA with 
molecular targets can be parsed using specific bioinfor-
matic resources. Fate acquisition is driven by splice vari-
ance that occurs as a result of differential mRNA process-
ing, and distinguishing these permutations from variations 
in background noise requires intensive computational 
resources (41). Development-dependent isoform switch-
ing presents another critical variable to temporal resolu-
tion of the transcriptome assembly during differentiation/
reprogramming (42,43). In addition, high degrees of post-
transcriptional regulation conferred by microRNA and long 
ncRNA mandates novel biostatistical models and in silico 
approaches to properly resolve transcriptome dynamics of 
fate commitment/reversion (44,45).
Ultimately, deeper data sets empower in silico tools, and 
is key to modern diagnostic techniques that employ next 
generation sequencing to leverage rich genomic and tran-
scriptomic content against clinical diseases in order to fa-
cilitate high resolution etiology definition (46). Paired with 
quality biobank sample acquisition and leading-edge 
techniques for cell isolation and reprogramming, continu-
ous development of high quality, publicly available com-
putational tools will significantly advance transcriptome 
analysis, and will refine transcriptome interrogation as a 
modern tool for assaying gene expression dynamics asso-
ciated with clinical pathologies.
PRoTeomiCS
The proteome consists of all proteins expressed by a ge-
nome in a defined cell or tissue at a particular time, 
whereas proteomics comprises an array of techniques for 
studying expression, abundance, structure (including post-
translational modifications) and function, including their 
physical and functional interactions (3). Modern proteom-
ic approaches involve high throughput protein separation 
and processing followed by mass spectrometry for pep-
tide and protein identification, either as intact entities or as 
peptide fragments, defined respectively as top-down and 
bottom-up proteomics (3). As proteins form the molecular 
machinery of the cell, alterations in their abundance and 
activity translate into detectable changes in other “-omic” 
strata, such as epigenetic modifications, mRNA abundance 
or differential splicing, and altered metabolite levels. Thus, 
comprehension of stem cell proteomes and their dynamics 
may provide detailed systems understanding of pluripoten-
cy, how it differs from somatic cell states, and may yield im-
portant clues into mechanistic understanding of progeni-
tor cells for therapeutic and diagnostic applications.
Proteomic studies have increased our understanding of 
protein complexes and dynamics contributing to cell fate 
determination, of cell state transitions during develop-
ment and reprogramming cells to pluripotency, and of the 
extensive molecular impact mediated by disease-targeted 
stem cell-based therapy. An expanded pluripotency net-
work described by proteomic assessment of protein-pro-
tein interactions between known transcription regulatory 
factors required for maintenance of ES cells identified com-
binatorial effects of transcriptional activator complexes re-
quired for pluripotency, together with repressor complex-
es necessary to prevent expression of proteins associated 
with differentiated cells (47-49).
Stoichiometric correlation between proteins and tran-
scripts can vary (50), and proteomic deconvolution per-
formed in conjunction with other “-omic” studies can 
enhance systems level analyses (51). For example, in a 
transcriptome/proteome study that employed chroma-
tin occupancy interrogation with focused epigenom-
ic tracking, discrete transcript and protein changes were 
revealed to be characteristic of cells released from pluri-
potency via NANOG depletion (52). This study also dem-
onstrated that epigenetic and post-transcriptional effects 
targeted distinct subgroups of cellular processes and func-
tions during differentiation, thus emphasizing fine dynam-
ic regulation in and among transcriptome and proteome 
layers. Furthermore, proteomic characterization of repro-
grammed somatic cells (53,54) has significantly identified a 
highly coordinated biphasic temporal dynamic driving in-
duced pluripotency (55). In another methodological com-
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bination study, (metabo)proteomic profiling was used to 
demonstrate enzymatic restructuring consistent with me-
tabolomic transition from an oxidative to a glycolytic me-
tabolomic phenotype that precedes and guides cell repro-
gramming (56).
Proteomic studies are also being used to define function-
al consequences of stem cell-based therapy. For example, 
extensive proteomic remodeling underlying structural and 
functional changes associated with onset of dilated cardi-
omyopathy was reversed by ES cell therapy, with derived 
protein networks exhibiting a pro-cardiogenic develop-
mental response with concomitant demotion of dysfunc-
tional disease-associated categories (57). Ultimately, the 
proteomic signature served as a diagnostic of stem cell re-
pair in the setting of dilated cardiomyopathy. Collectively, 
these studies demonstrate the power of proteomics and 
of integrative systems biology strategies incorporating 
proteomics to elucidate molecular properties associated 
with maintenance or attainment of pluripotency, mecha-
nistic underpinnings of the reprogramming process, and 
of stem cell therapeutic proteome remodeling in the set-
ting of clinical disease.
meTAboLomiCS
The metabolome consists of small molecular weight com-
pounds that undergo chemical transformation within the 
cell. Metabolomics captures the complexity of global me-
tabolism in the context of (patho)physiology, and a mul-
titude of analytical tools have been developed to detect 
metabolite levels, such as enzymatic analysis, flame ion-
ization, and Raman/Fourier transformed infrared and UV-
VIS spectroscopy. Nuclear magnetic resonance (NMR) and 
mass spectrometry have become methods of choice due 
to their ability to resolve a wide range of chemical moieties 
in a high throughput manner (58). The majority of studies 
to date have utilized targeted approaches to interrogate a 
defined set of metabolites relevant to a specific biological 
question. However, with advances in instrumentation, data 
analysis and compound annotation, broadly inclusive shot-
gun approaches are routinely employed to reveal a more 
global profile (59). Resolution of intracellular (fingerprint) 
and extracellular (footprint) metabolomes has provided in-
sight into metabolic restructuring that guides stem cell dif-
ferentiation and dedifferentiation (56,60,61). Multiplexing 
of metabolomics technologies with stable-isotope assess-
ment of metabolic fluxes will further enable dissection of 
intimate metabolite dynamics to establish metabolic maps 
defining cell fate.
To bridge the genotype-phenotype continuum, metab-
olite screening offers a minimally invasive diagnostic ap-
proach associated with high patient value and can pro-
vide a wealth of information as metabolite profiles serve as 
functional signatures of enzymatic activity (59). Metabolo-
mic analysis of clinically relevant pathologies enables iden-
tification of key metabolites abnormal in identity or quan-
tity. These disease state biomarkers offer fast, reproducible, 
and cost-effective identification of present or putative dis-
ease states (62). Presently, widespread and robust clinical 
applications of metabolite profiling include screening for 
inborn errors of metabolism, which is now routinely per-
formed in most of the developed world (63). Targeted tan-
dem mass spectrometry based screening of approximately 
30-40 metabolites, with emphasis placed on amino acids 
and acylcarnitines, now enables diagnosis of over 30 dif-
ferent metabolic disorders, and with greater efficacy than 
clinical screening alone (64).
A growing number of studies have utilized metabolomic 
techniques to examine stem cell biology, critical for defin-
ing the baseline stem cell metabolic landscape and its per-
turbation in the diseased state, as well as identifying princi-
pal roles of energy metabolism in controlling stem cell fate 
(65-67). This fundamental work has laid the groundwork 
for application of stem cell metabolomics as a platform 
for pharmaceutical toxicity screening and identification 
of predictive biomarkers of toxicity. Indeed, ES cells treat-
ed with valproate were distinguished from vehicle-treat-
ed cells based upon a metabolic signature encompassing 
kynurenine and glutamate metabolism (68-70), demon-
strating utility in applying metabolomics deconstruction 
against an ES cell derived investigative platform, that can 
ultimately be refined for clinical application.
TRAnSLATionAL APPLiCATion oF neTWoRK bioLogY
Genomic, transcriptomic, proteomic, and metabolomic net-
works possess unique traits that endow these strata with 
qualities suitable for use as clinical tools, yet an added level 
of diagnostic sophistication may be accomplished by lever-
aging the integrated molecular architecture of these net-
works against complex disease phenotypes. Network biolo-
gy, as part of a clinical management strategy, can potentially 
be employed to identify molecular candidates for pharma-
cological intervention (71,72). Dissection of molecular inter-
actions presents an opportunity to integrate these “-omic” 
layers to elucidate the systems etiology of disease occur-
rence and progression through study of the flow of bio-
logical information in and among these layers (73).
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Biological networks possess a discriminant set of charac-
teristics that can be quantified (74,75). This information 
can be used to identify critical genes, proteins, or me-
tabolites in their respective networks that measures not 
only output of the system, ie, phenotype, but may provide 
information on biological robustness as well as informa-
tional flow (76). Thus, comprehensive molecular cartogra-
phy through innovative and cutting edge high through-
put methodologies can define the functional landscape, 
or interactome, underlying development and disease 
(77,78). Furthermore, biological network analysis provides 
dynamic metrics that permit navigation of this function-
al topography, serving as a molecular positioning system 
that identifies features of the interactome critical to main-
tenance of system function and crucial for targeted inter-
ventional translational strategies (9).
STem CeLL inFoRmATiCS: A noVeL DiAgnoSTiC 
PARADigm
Systems biology integrates multiple disciplines to create a 
novel area for translational application, yet faces a pletho-
ra of challenges that constrain full implementation. High 
throughput techniques are expensive and availability to 
clinical populations at present is financially prohibitive, but 
as technology improves and assay costs diminish, applica-
tion of these techniques to the greater clinical population 
becomes feasible (79). For example, the speed and vol-
ume of whole genome sequencing has increased dramati-
cally while concomitantly becoming less expensive in the 
past decade (80), and continuation of this trend with other 
“-omic” technologies (81) will ultimately realize translation-
ally applicable personalized bioinformatics (82).
FiguRe 1. implementation of advanced diagnostics facilitated by leading generation stem cell informatics. A comprehensive sys-
tems biology approach using integrated high throughput screening approaches in combination with the power of reprogrammed 
(induced pluripotent) stem cells can provide a depth of resolution that can be leveraged against poorly characterized disease etiol-
ogy. in the illustrated scheme, patient stratification into healthy and diseased cohorts initiates this advanced diagnostic paradigm 
(I). isolation of cells from patients with diseased tissue can be reprogrammed to an embryonic state (II), providing potential zero 
(embryonic) and end stage (differentiated) time points for longitudinal next generation assays. generation of individualized and 
comprehensive multidimensional biological data sets at genome, transcriptome, proteome, and metabolome levels (III) can provide 
advanced clinical resources to track disease progression in real time (systems biology integration) that may be used in construction 
of an integrated and dynamic network signature (IV) to identify novel molecular targets for therapeutic intervention (red circles) in 
the original patient cohort (reiterative signature diagnostics).
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Another parameter associated with high throughput ap-
proaches is generation of massive amounts of biodata (83). 
Logistics of data storage and recovery become critical fac-
tors for consideration as a clinically relevant resource, and 
to address this need, optimization of cloud server storage 
technology presents an attractive option as a readily acces-
sible and dynamic electronic bioarchive (84). Indeed, con-
tinuous development of added-value electronic databases 
indicates that this growing need to store and parse intricate 
data sets is actively being addressed (85). It is anticipated 
that petabytes to exabytes of next generation biodata (86) 
will emerge in coming years, and for bioinformatic decon-
volution to remain practical, cloud-based systems capable 
of handling these computationally intensive data sets are 
considered viable platforms to address this need (87). This is 
particularly critical for temporal profiling that requires inte-
gration of molecular data measured over a chronologically 
ordered series of developmental or disease stages (88,89).
TRACing moLeCuLAR SignATuReS FRom benCh To 
beDSiDe enViSioneD
Technology development in the post-genomic area has giv-
en rise to advanced high throughput methodologies and 
modern, integrative bioinformatic tools that permit an un-
precedented level of molecular resolution. Dissection of 
these discrete, yet interrelated molecular strata, in combina-
tion with the ability to reprogram phenotypically commit-
ted cells to a pluripotent state that provides a unique and 
patient-specific embryonic pool of cells, enables feasible 
dynamic and individualized diagnostic strategies for trans-
lational application (90-93). For the first time, multiple mo-
lecular networks underlying clinical dysfunctions can be 
mapped and utilized to trace disease etiology (Figure 1). 
Furthermore, development of a prototype platform for stem 
cell diagnostics, which incorporates major “-omic” layers dis-
cussed here, provides the premise for incorporating other 
“-omes” for enhanced systems biology deconvolution of dis-
ease states. Implementation of this approach as part of a re-
cursive diagnostic algorithm offers the potential for an en-
hanced modality of patient care made possible by a current 
medical zeitgeist constructed on an array of novel post-ge-
nomic knowledge (94). Ultimately, a collective and dynamic 
electronic repository for the diversity of biodata constantly 
generated by leading edge high throughput technology 
enables powerful meta-level analyses with unmatched pre-
cision applicable to multiple disease models (95-98).
Resetting diseased cells to a pluripotent state provides op-
portunities to track patient-specific changes at primary 
(genomic), secondary (transcriptomic), tertiary (proteom-
ic), and quaternary (metabolomics) molecular network 
strata. Construction of an accessible electronic archive, to 
house large volumes of biodata produced from high grade 
bioinformatics analyses, is critical for establishing a dynam-
ic clinical resource essential to fully realize comprehensive 
ad hoc diagnosis and real-time molecular tracking of pa-
tient pathology and disease progression.
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